Madrigal pharmaceuticals to announce topline results from the phase 3 maestro-nafld-1 study of resmetirom on monday, january 31st

Conshohocken, pa., jan. 30, 2022 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq: mdgl), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, plans to announce topline results from the phase 3 maestro-nafld-1 study of resmetirom on monday, january 31st, 2022.
MDGL Ratings Summary
MDGL Quant Ranking